Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging : Mass Spectrometry - One of the pillars of ProteomicsMARKO-VARGA, György; FEHNIGER, Thomas E; REZELI, Melinda et al.Journal of proteomics (Print). 2011, Vol 74, Num 7, pp 982-992, issn 1874-3919, 11 p.Article

Syndrome mains-pieds : nouvel effet secondaire de l'erlotinib = Hand-foot syndrome : A new side effect of erlotinibROUXEL, A.-M; ROGUEDAS, A.-M; DESCOURT, R et al.Annales de dermatologie et de vénéréologie. 2008, Vol 135, Num 11, pp 762-764, issn 0151-9638, 3 p.Article

2009: l'année de la maintenance en première ligne ? = 2009: the year of first-line maintenance?PEROL, M.Revue de pneumologie clinique (Paris). 2009, Vol 65, issn 0761-8417, S75-S79, SUP2Conference Paper

Erupción acneiforme inducida por erlotinib que respeta el área de piel previamente irradiada = Eriotinib-induced acneiform rash not affecting previously irradiated skinEGUREN, C; DOMINGUEZ-FERNANDEZ, I; SANTIAGO-SANCHEZ-MATEOS, D. I et al.Actas dermo-sifiliográficas (Ed. impresa). 2010, Vol 101, Num 2, pp 186-187, issn 0001-7310, 2 p.Article

Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation fieldCHIU, H. Y; CHENG, Y. P; JEE, S. H et al.Clinical and experimental dermatology (Print). 2012, Vol 37, Num 8, pp 922-924, issn 0307-6938, 3 p.Article

Metabolic profiling identifies lung tumor responsiveness to erlotinibFAN, Teresa W.-M; LANE, Andrew N; HIGASHI, Richard M et al.Experimental and molecular pathology. 2009, Vol 87, Num 1, pp 83-86, issn 0014-4800, 4 p.Article

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLCPALLIS, A. G; SYRIGOS, K. N.Lung cancer. 2013, Vol 80, Num 2, pp 120-130, issn 0169-5002, 11 p.Article

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancerJEFFREY PETTY, W; VOELZKE, William R; URBANIC, James J et al.Lung cancer. 2011, Vol 74, Num 3, pp 384-391, issn 0169-5002, 8 p.Article

Generalized Xerotic Dermatitis with Neutrophilic Spongiosis Induced by Erlotinib (Tarceva®)LÜBBE, J; MASOUYE, I; DIETRICH, P.-Y et al.Dermatology (Basel). 2008, Vol 216, Num 3, pp 247-249, issn 1018-8665, 3 p.Article

Significant drug interaction : Phenytoin toxicity due to erlotinibGRENADER, Tal; GIPPS, Maya; SHAVIT, Linda et al.Lung cancer. 2007, Vol 57, Num 3, pp 404-406, issn 0169-5002, 3 p.Article

Comparing the effects of Fe(III) and Cu(II) on the binding affinity of erlotinib to bovine serum albumin using spectroscopic methodsYAN LIU; MINGMAO CHEN; LING SONG et al.Journal of luminescence. 2013, Vol 134, pp 515-523, issn 0022-2313, 9 p.Article

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literatureTER HEINE, R; VAN DEN BOSCH, R. T. A; SCHAEFER-PROKOP, C. M et al.Lung cancer. 2012, Vol 75, Num 3, pp 391-397, issn 0169-5002, 7 p.Article

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutationsWU, Jenn-Yu; WU, Shang-Gin; YANG, Chih-Hsin et al.Lung cancer. 2011, Vol 72, Num 2, pp 205-212, issn 0169-5002, 8 p.Article

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer PatientsWOJAS-KRAWCZYK, Kamila; KRAWCZYK, Paweł; MLAK, Radosław et al.Respiration (Basel). 2011, Vol 82, Num 4, pp 341-350, issn 0025-7931, 10 p.Article

Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancerTSUCHIYA, Takanori; FUKUDA, Takashi; FURUIYE, Masashi et al.Lung cancer. 2011, Vol 74, Num 3, pp 521-528, issn 0169-5002, 8 p.Article

Clinical development of EGFR-tyrosine kinase inhibitors in JapanNAKAGAWA, Kazuhiko.Cancer chemotherapy and pharmacology. 2006, Vol 58, issn 0344-5704, s33-s37, SUP1Conference Paper

The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joiningKRIEGS, Malte; KASTEN-PISULA, Ulla; RIECKMANN, Thorsten et al.DNA repair. 2010, Vol 9, Num 8, pp 889-897, issn 1568-7864, 9 p.Article

Les inhibiteurs d'EGFR dans le cancer bronchique non à petites cellules: plus qu'hier et moins que demain = EGFR inhibitors in non-small cell lung cancer: More than yesterday (but less than tomorrow)CORTOT, A. B.Revue de pneumologie clinique (Paris). 2010, Vol 66, Num 6, pp 367-374, issn 0761-8417, 8 p.Article

Erlotinib in cancer treatmentBARESCHINO, M. A; SCHETTINO, C; TROIANI, T et al.Annals of oncology. 2007, Vol 18, issn 0923-7534, vi35-vi41, SUP6Conference Paper

Erlotinib-responsive actinic keratosesHERMANNS, Jean-Francois; PIERARD, Gerald E; QUATRESOOZ, Pascale et al.Oncology reports. 2007, Vol 18, Num 3, pp 581-584, issn 1021-335X, 4 p.Article

Sécurité de la réintroduction de l'erlotinib à faible posologie après un syndrome main-pied induit par l'erlotinib dans une tumeur de Pancoast-Tobias = Safety of reintroduction of erlotinib at low doses following hand-foot syndrome induced by erlotinib treatment for a Pancoast-Tobias tumourCLAUSE, A.-L; VANDERHEYDE, K; PIETERS, T et al.Revue des maladies respiratoires. 2014, Vol 31, Num 7, pp 628-631, issn 0761-8425, 4 p.Article

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancerLI, Yuan-Yuan; LAM, Sze-Kwan; MAK, Judith Choi-Wo et al.Lung cancer. 2013, Vol 81, Num 3, pp 354-361, issn 0169-5002, 8 p.Article

Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinibASAMI, Kazuhiro; KAWAHARA, Masaaki; ATAGI, Shinji et al.Lung cancer. 2011, Vol 73, Num 2, pp 211-216, issn 0169-5002, 6 p.Article

The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primatesMEANY, Holly J; FOX, Elizabeth; MCCULLY, Cynthia et al.Cancer chemotherapy and pharmacology. 2008, Vol 62, Num 3, pp 387-392, issn 0344-5704, 6 p.Article

EGFR kinase domain mutations - : functional impact and relevance for lung cancer therapyIRMER, D; FUNK, J. O; BLAUKAT, A et al.Oncogene (Basingstoke). 2007, Vol 26, Num 39, pp 5693-5701, issn 0950-9232, 9 p.Article